Rephonic
Artwork for Pathfinders in Biopharma

Pathfinders in Biopharma

RBC Capital Markets
FDA
Biotech
Biotechnology
Mergers and Acquisitions
Psychedelic Medicine
Clinical Trials
Pharmaceuticals
Investment Strategies
Clinical Data
IPO Activity
Drug Discovery
Glp-1
Obesity Treatments
Mast Cell Diseases
RBC Capital Markets
Venture Capital
Inflation Reduction Act
Biopharma
AI In Healthcare
Wet AMD

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.

PublishesTwice weeklyEpisodes60Founded6 years ago
Number of ListenersCategories
NewsBusinessBusiness NewsInvesting

Listen to this Podcast

Artwork for Pathfinders in Biopharma

Latest Episodes

Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s ambitions, and the expansion effo... more

YouTube

This episode of RBC Pathfinders in Biopharma explores how next-generation retinal gene therapies could transform treatment for patients with wet AMD and diabetic macular edema. CCBO of 4D Molecular Therapeutics, Chris Simms, discusses the promise of ... more

YouTube

The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC’s Global Healthcare Conference, Hunter Ham... more

YouTube

A growing number of biotechs are defying the perception that you need the might of big pharma to launch a new drug. But there’s always the prospect of an offer that simply can’t be refused. Three leaders who recently sold companies – Whit Bernard (Me... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more
Exchanges
ExchangesGoldman Sachs

Recent Guests

Hunter Hammond
From Capstone Strategy Group
Capstone Strategy Group
Episode: Why the MFN price battle is heading for court, not legislature
Will Humphrey
From Capstone Strategy Group
Capstone Strategy Group
Episode: Why the MFN price battle is heading for court, not legislature
Chris Simms
Chief Commercial and Business Officer at 4D Molecular Therapeutics
4D Molecular Therapeutics
Episode: 4DMT targets global retina market with long-lasting genetic treatment
Leonid Timashev
Biotechnology Analyst at RBC Capital Markets
RBC Capital Markets
Episode: Is this finally the breakthrough moment for psychedelic therapies?
Rob Barrow
CEO of MindMed, a clinical stage company at the forefront of psychedelic drug development.
MindMed
Episode: MindMed: Rethinking brain health with psychedelic therapy
George Elston
Chief financial officer and head of corporate development at Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals
Episode: Funding the future of retinal health with Eyepoint
Paris Panayiotopoulos
Senior Managing Director at Blackstone Life Sciences and member of its investment committee.
Blackstone Life Sciences
Episode: How Blackstone Life Sciences is bridging the innovation gap
Kabir Nath
Chief Executive Officer of Compass Pathways, a biotechnology company focusing on mental health therapies.
Compass Pathways
Episode: Compass trials mark a milestone moment for the psychedelics sector
Dr. Jeff Stein
President and CEO of Cidara Therapeutics
Cidara Therapeutics
Episode: Cidara’s pursuit of universal flu protection with a single dose

Host

Joe Coletti
Host of Pathfinders in Biopharma, RBC Capital Markets

Reviews

4.9 out of 5 stars from 15 ratings
  • JMC

    Rare to find a podcast focused on the capital markets side of biotech. Very substantive and knowledgeable conversations. Great episode with Omega and Nuvation, keep those coming!

    Apple Podcasts
    5
    JCChat109
    United States5 years ago
  • Learned Tons!

    I’m a seasoned angel investor in biotech and I find this podcast really valuable. Every episode has added to my knowledge of both the science and the finance. It fills an important void in the podcast space. Well done team RBC Capital Markets.

    Apple Podcasts
    5
    Sal from Cambridge
    United States5 years ago
  • Great podcast!

    Very informative!

    Apple Podcasts
    5
    GloriaM21
    United States6 years ago
  • Great Insights

    I enjoyed every episode, looking forward to more insight.

    Apple Podcasts
    5
    Mzushi
    United States6 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Valuable for seasoned biotech angels and investors; blends science with finance
Informative and well-executed, with practical takeaways for investors and sponsors
Substantive biotech finance discussions and knowledgeable guests
Consistently insightful with strong guest lineups and market context

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#70
Israel/Business/Investing
Apple Podcasts
#222
Israel/Business

Talking Points

Recent interactions between the hosts and their guests.

4DMT targets global retina market with long-lasting genetic treatment
Q: What makes 4D150 differentiating in a crowded retina gene therapy space?
The differentiation centers on a safety-first approach with the R100 vector, delivering a lower dose that maintains efficacy and minimizes intraocular inflammation, which supports a strong safety profile crucial for physician and patient trust in a chronic therapy.
Funding the future of retinal health with Eyepoint
Q: How is Eyepoint navigating potential FDA impacts with its DuraView program?
Eyepoint has had robust interactions with the FDA, maintaining consistency in the regulatory process without any significant changes in oversight.
Funding the future of retinal health with Eyepoint
Q: How is Eyepoint positioning itself to lead in retinal disease treatments?
Eyepoint is focused on leveraging its DuraCert technology to deliver drugs effectively to the back of the eye, introducing a new mechanism of action in treating wet AMD.
Funding the future of retinal health with Eyepoint
Q: How is Eyepoint managing its capital allocation priorities right now?
Eyepoint is in a strong capital position, funded through its ongoing trials into 2027, and is focusing on executing their strategies for the completion and preparation for the NDA filing.
How Blackstone Life Sciences is bridging the innovation gap
Q: How do you balance selective governance, operational involvement and risk to hit those impressive outcomes?
Paris details the factors contributing to their high phase three success rate, including their team's expertise and thorough diligence process.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Pathfinders in Biopharma

What is Pathfinders in Biopharma about and what kind of topics does it cover?

Shows focus on capital markets, investing, and strategic developments in biopharma. Episodes cover sector health, financing trends, M&A, regulatory dynamics, and breakthrough therapies across areas like cancer, psychedelics, retinal diseases, and AI-enabled drug discovery. Noteworthy is the strong investor and RBC Capital Markets lens, bringing high-level financial analysis to scientific and clinical progress, plus guest profiles that span CEOs, CFOs, and top-tier biopharma financiers. This combination offers listeners practical insight for evaluating deals, partnerships, and market timing in a fast-changing industry.

Where can I find podcast stats for Pathfinders in Biopharma?

Rephonic provides a wide range of podcast stats for Pathfinders in Biopharma. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Pathfinders in Biopharma and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Pathfinders in Biopharma get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for Pathfinders in Biopharma, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Pathfinders in Biopharma?

Rephonic provides comprehensive predictive audience data for Pathfinders in Biopharma, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Pathfinders in Biopharma have?

To see how many followers or subscribers Pathfinders in Biopharma has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Pathfinders in Biopharma?

These podcasts share a similar audience with Pathfinders in Biopharma:

1. BioCentury This Week
2. Biotech Hangout
3. The Readout Loud
4. The Meb Faber Show - Better Investing
5. Exchanges

How many episodes of Pathfinders in Biopharma are there?

Pathfinders in Biopharma launched 6 years ago and published 60 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Pathfinders in Biopharma?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Pathfinders in Biopharma?

Rephonic pulls ratings and reviews for Pathfinders in Biopharma from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Pathfinders in Biopharma?

Rephonic provides full transcripts for episodes of Pathfinders in Biopharma. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Pathfinders in Biopharma?

Recent guests on Pathfinders in Biopharma include:

1. Hunter Hammond
2. Will Humphrey
3. Chris Simms
4. Leonid Timashev
5. Rob Barrow
6. George Elston
7. Paris Panayiotopoulos
8. Kabir Nath

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days